Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      E-Cigarette Use and Bladder Cancer Risk: There May Be a Link

      May 26, 2017
      By Allie Casey
      Article

      A recent study provides more evidence toward the link between electronic cigarette use and bladder cancer risk.

      E-Cigarette Use and Bladder Cancer Risk: There May Be a Link

      E-Cigarette Use and Bladder Cancer Risk: There May Be a Link

      Findings of a pilot study offer more support for the link between smoking and bladder cancer—in this case, a possible elevated risk for the disease due to e-cigarette use.

      In an interview with Oncology Nursing News, study author Tatum Tarin, MD, provided a rationale for the study presented at the recent annual meeting of the American Urological Association (AUA).

      “One of the biggest impetuses for this study is that we know that e-cigarettes and vaping is a useful tool for people to stop smoking—sort of a safe alternative,” said Tarin, an assistant professor of urology at the University of Pittsburgh School of Medicine, specializing in urologic oncology.

      "There has been a 900% increase in e-cigarettes and vaping in kids who wouldn't be smoking otherwise. What we were trying to show is that in kids who are nonsmokers, this is not exactly a safe thing, or at least we don't know the full safety profile of electronic cigarettes and vaping."

      Although e-cigarettes may be safer than traditional cigarettes, the composition of the liquids in these devices is complex and unregulated. A wide variety of formulas are available, and some may contain known bladder carcinogens such as nitrosamines, formaldehyde, acrolein, metals, and acetaldehyde.

      The study reported at AUA noted that the urine samples of e-cigarette users contained some of those known carcinogens. Researchers collected urine samples from 13 e-cigarette users and 10 nonsmoking, non—e-cigarette using controls. Using liquid chromactography-mass spectrometry, they tested the samples for 5 molecules that are known to be bladder carcinogens and are either present in traditional cigarettes or common solvents believed to be used in some e-cigarette formulations: benzanthracene, benzopyrene, 1-hydroxypyrene, o-toluidine, and 2-napthylamine.

      Patients self-reported abstinence from traditional cigarettes for at least 6 months prior to the specimen collection; 9 of the 13 e-cigarette users reported that they were long-term (>12 months) nonsmokers.

      Twelve of the 13 samples from e-cigarette users (92%) tested positive for 2 of the carcinogenic compounds: o-toluidine, and 2-napthylamine. All samples from the 10 control patients tested negative for the 5 molecules. The other 3 carcinogens were not identified in any samples.

      Tarin explained that the 2 molecules identified, “have been studied for a very long time, mostly in environmental exposures. They’re known to be in people who smoked tobacco and used conventional cigarettes. O-toluidine and 2-napthylamine are known to be bladder cancer—causing agents.”

      Tarin also pointed out that in a survey of the 13 e-cigarette users, “Every single one thought there were no harmful, deleterious, side effects in electronic cigarettes. While they probably are a safer alternative to smoking, they are not completely safe. And that’s what we’re trying to show here. Compared to our control group of nonsmoker/non-electronic cigarette users, [e-cigarette users] had higher levels of these bladder carcinogens.”

      Researchers determined that further studies are needed to clarify the safety profile of e-cigarettes and their role in elevating bladder cancer risk, given the higher concentration of carcinogenic compounds in the urine samples of the e-cigarette users in this study.

      “It will be important to try and quantify in the long-term, what is the actual effect on bladder cancer [risk] or patients with bladder cancer,” Tarin noted. “The issue is, there are kids that are doing this. We don’t want to be 50 years down the road, saying, ‘Oh my god, we thought this was safe, but actually there’s a problem.’”

      ______________________________________________________________________________

      Fuller T, Acharya A, Bhaskar G, Yu M, Little S, Tarin T. MP88-14 evaluation of e-cigarettes usersurine for known bladder carcinogens. J Urol. 2017;197(4):e1179.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Man standing in front of Oncology Nursing News-branded backdrop
      Brenda Martone
      Arash Rezazadeh Kalebasty
      Leapman
      Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
      Related Content

      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Rendering of prostate cancer cells

      Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

      Darlene Dobkowski, MA
      February 13th 2025
      Article

      With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.


      Rendering of a bladder and prostate, surrounded by images of cancerous cells

      Talazoparib-Enzalutamide Combo Increases OS in mCRPC

      Jordyn Sava
      February 13th 2025
      Article

      Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

      Related Content

      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Rendering of prostate cancer cells

      Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

      Darlene Dobkowski, MA
      February 13th 2025
      Article

      With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.


      Rendering of a bladder and prostate, surrounded by images of cancerous cells

      Talazoparib-Enzalutamide Combo Increases OS in mCRPC

      Jordyn Sava
      February 13th 2025
      Article

      Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

      Latest Conference Coverage

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.